Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Aug 26;6(3):68.
doi: 10.3390/ijns6030068. eCollection 2020 Sep.

The Success of a Screening Program Is Largely Dependent on Close Collaboration between the Laboratory and the Clinical Follow-Up of the Patients

Svetlana Lajic  1   2 , Leif Karlsson  1   3 , Rolf H Zetterström  3   4 , Henrik Falhammar  4   5 , Anna Nordenström  1   2   3
Affiliations
Review

The Success of a Screening Program Is Largely Dependent on Close Collaboration between the Laboratory and the Clinical Follow-Up of the Patients

Svetlana Lajic et al. Int J Neonatal Screen. .

Abstract

Neonatal screening for congenital adrenal hyperplasia due to 21-hydroxylase deficiency is now performed in an increasing number of countries all over the world. The main goal of the screening is to achieve early diagnosis and treatment in order to prevent neonatal salt-crisis and death. The screening laboratory can also play an important role in increasing the general awareness of the disease and act as the source of information and education for clinicians to facilitate improved initial care, ensure prompt and correct glucocorticoid dosing to optimize the long-term outcome for the patients. A National CAH Registry and CYP21A2 genotyping provide valuable information both for evaluating the screening program and the clinical outcome. The Swedish experience is described.

Keywords: 21-hydroxylase deficiency; CAH; congenital adrenal hyperplasia; long-term outcome; neonatal screening.

PubMed Disclaimer

Conflict of interest statement

Conflicts of InterestThe authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Flow chart for the neonatal screening, 17OHP cut-off levels, information, and investigations.
See this image and copyright information in PMC

References

    1. Speiser P.W., Arlt W., Auchus R.J., Baskin L.S., Conway G.S., Merke D.P., Meyer-Bahlburg H.F.L., Miller W.L., Murad M.H., Oberfield S.E., et al. Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 2018;103:4043–4088. doi: 10.1210/jc.2018-01865. - DOI - PMC - PubMed
    1. Nordenstrom A., Ahmed S., Jones J., Coleman M., Price D.A., Clayton P.E., Hall C.M. Female preponderance in congenital adrenal hyperplasia due to CYP21 deficiency in England: Implications for neonatal screening. Horm. Res. 2005;63:22–28. doi: 10.1159/000082896. - DOI - PubMed
    1. White P.C. Optimizing newborn screening for congenital adrenal hyperplasia. J. Pediatr. 2013;163:10–12. doi: 10.1016/j.jpeds.2013.02.008. - DOI - PubMed
    1. Thilén A., Nordenstrom A., Hagenfeldt L., von Dobeln U., Guthenberg C., Larsson A. Benefits of neonatal screening for congenital adrenal hyperplasia (21-hydroxylase deficiency) in Sweden. Pediatrics. 1998;101:E11. doi: 10.1542/peds.101.4.e11. - DOI - PubMed
    1. Gidlof S., Wedell A., Guthenberg C., von Dobeln U., Nordenstrom A. Nationwide neonatal screening for congenital adrenal hyperplasia in sweden: A 26-year longitudinal prospective population-based study. JAMA Pediatr. 2014;168:567–574. doi: 10.1001/jamapediatrics.2013.5321. - DOI - PubMed

LinkOut - more resources